| GTO ID | GTC3788 |
| Trial ID | NCT06295809 |
| Disease | Squamous Cell Carcinoma | Skin Neoplasm |
| Therapy | mRNA vaccine |
| Treatment | V940|mRNA-4157 |
| Co-treatment | Pembrolizumab |
| Phase | Phase2|Phase3 |
| Recruitment status | Not Recruiting |
| Title | A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant V940 (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007) |
| Year | 2024 |
| Country | United States |
| Company sponsor | Merck Sharp & Dohme LLC |
| Other ID(s) | V940-007|2023-505712-37|U1111-1292-3589|V940 |
| Vector information | |||
|
|||
| Cohort1: V940_Pembrolizumab_Surgery | |||||||||
|
|||||||||
| Cohort2: Surgery | |||||||||
|
|||||||||
| Cohort3: Pembrolizumab_Surgery | |||||||||
|
|||||||||